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Abstract
Background: Drugs used during pregnancy can adversely affect the health and life of the mother and unborn
child. However, the fact that drugs are needed to mitigate complications during pregnancy cannot be avoided. The
present study was designed to identify the common complications during pregnancy and assess the medications
that have been used to mitigate those complications in an attempt to improve drug prescribing during pregnancy.
Methods: A hospital based cross sectional study was conducted at Manipal Teaching Hospital, Nepal in 275
pregnant women presenting with at least one complication and the drugs prescribed for the management of
those complications were analyzed.
Results: Majority of the patients in this study were in the age group 20–24 (44 %) and in the third trimester (53.8 %).
Maximum patients complained pain (back, abdominal, lower abdominal, neck, pelvic) as primary complication (24.3 %)
which was followed by nausea/vomiting, upper respiratory tract complications, acid reflux disease and others. Of the total
prescriptions eighty six (86) did not have any medicines prescribed to the patients except multivitamins and nutritional
supplements. The average drugs prescribed per patient was 2.78 in outpatient setting and 5.41 in in-patients. Ranitidine,
hyoscine butylbromide, paracetamol were the most frequently prescribed medications. Antimicrobials comprised
12.8 % of total drugs prescribed and 18 % of total drugs were fixed dose combinations. Two hundred and thirty
four (234) prescriptions out of 275 were prescribed by brand names. Most of the prescribed drugs were from FDA
pregnancy category B and C.
Conclusion: The present finding showed that pregnant patients were prescribed medications almost only when
necessary and those considered safe during pregnancy were chosen to a large extent. However, few teratogenic
drugs (2.49 % of total drugs prescribed) were also found to be prescribed which might need further assessments.
Keywords: Pregnancy, Complication, Management, Drug utilization, Nepal
Background
Pregnancy is associated with a wide range of pharmaco-
kinetic [1, 2] and physiological [3, 4] changes. Those
changes quite often present physiological complications
during pregnancy. Apart from this, pregnant women also
present with other concurrent medical illness [5, 6] and
chronic diseases. Irrespective of the risk of drug ther-
apy during pregnancy, drug use cannot be avoided in
conditions where benefits potentially outweigh the
risks involved [7]. The risks associated with drug use
in pregnancy can be two fold: incidence of adverse
effects to the mother followed by teratogenic effects
to the growing fetus [8, 9]. This demands that a
careful consideration is required before drugs are
prescribed to pregnant patients.
It is also a common practice to use iron, calcium, multi-
vitamins, folic acid and other nutritional supplements
during pregnancy to replenish for any nutritional deficien-
cies. Use of herbal and homeopathic supplements/medi-
cines is also common [10]. Many researches have been
conducted worldwide for assessing the occurrence of
complications and drug utilization patterns [5–7, 11–13]
during pregnancy despite of which safety of each drug has
* Correspondence: rameshlog@hotmail.com
1Department of Drug Administration, Kathmandu, Nepal
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Devkota et al. BMC Pregnancy and Childbirth  (2016) 16:272 
DOI 10.1186/s12884-016-1068-8
not been established. Although rare, studies demonstrate
the prescription and use of drugs from FDA category X
during pregnancy [6, 11–13].
Nearly 18.5 % of the diseases among women of repro-
ductive age are related to pregnancy related complica-
tions [14] and deaths due to those complications is
higher in developing nations. Nepal has a maternal mor-
tality ratio of 170 per 100,000 live births [15] which is
one of the worst figures in south Asia. Postpartum
hemorrhage, eclampsia, infections, obstructed labor,
complications of abortions are the major causes of
maternal mortality in Nepal [14]. More than 42 % of the
adult population in Nepal is illiterate and when com-
pared to sex ratio, it is higher among females [16]. This
literally means that pregnant women would know less
about medications prescribed to them which demands
for effective rational prescribing. Moreover, there are
limited researches in medication use during pregnancy
in Nepal for which we decided to carry out this study. If
the common complications during pregnancy were to be
known, healthcare facilities would try to accommodate
necessary resources in advance so that the problems
could be dealt with ease. This knowledge used alongside
rational prescribing which taken into account for the
low literacy rate of Nepal could prevent any un-intended
drug induced risk to the mother and child. Thus this
study was carried out with the aim to find out the type
and nature of common pregnancy complications (arising
either due to physiological changes or any other associ-
ated medical illness) in Western Nepal and access the
medications used to mitigate those complications in an
attempt to improve the drug prescribing patterns during
pregnancy.
Methods
Study design, site, sample size and duration of study
This was a hospital based cross-sectional study, car-
ried out at Obstetrics and Gynecology (OBG) Ward
of Manipal Teaching Hospital, Fulbari, Kaski, Nepal from
July to December 2013. Manipal Teaching Hospital is a
750 bed community based tertiary care hospital located at
the Western Region of Nepal. A total of 275 prescriptions
of pregnant women with various complications were
included in this study.
Ethical consideration
The study was ethically approved by Manipal Teaching
Hospital, Kaski, Nepal. Informed consent was taken
from the patients at the time of enrollment in the study.
Sampling technique and Inclusion criteria
Simple purposive sampling technique was used to select
the subjects for the study. The pregnant women who
visited the hospital during the study duration and
presented with at least one newly diagnosed complica-
tion were included for the study. Any associated physio-
logical, medical, obstetrical, gynaecological condition
identified by the consulting physician as an illness and
mentioned in the prescription of the patient has been
considered as a complication in this study. Any patient
coming for follow-up was not included in the study to
avoid the repetition of prescriptions. Hence, 275 pre-
scriptions represent 275 individual patients with compli-
cations. Both out-patient and in-patient prescriptions
were studied. In case of admitted patients, the prescrip-
tions were studied only once. All patients approached
responded to us and thus the response rate was 100 %.
Exclusion criteria
Pregnant women who did not present with any compli-
cations and those who had complications before the
time of study duration were not included in the study.
Data collection
Characteristics related to patient demographics, compli-
cations and medicines used for the treatment of those
complications were collected in the proforma designed
for the same. Medications prescribed by the physicians
at the time of consultation were included in the study.
Data on self medications and/or any other medication
being taken besides those prescribed at that point of
time were not collected.
Statistical analysis
Medicines were classified according to the Anatomic
Therapeutic Chemical (ATC) and US Food and Drug
Administration (FDA) risk classification. Data were ana-
lyzed by statistical package for social sciences (SPSS)
software version 22. Descriptive statistics, in the form of
frequency distribution and associated percentage, were
employed for the presentation of complications and
medicines used for their management. Associations
among complications, age and trimester of the respon-
dents were analyzed by Chi square test and/or Fisher’s
exact test (where the individual cell frequencies were less
than 5). The p value <0.05 was considered statistically
significant at 95 % confidence interval.
Results
Demographic details
Majority of the patients in the study were from the age
group 20–24 (44 %), which was followed by age group
25–29 (32.7 %), 15–19 (12.4 %), 30–34 (9.8 %), 35–39
(0.7 %) and 40–44 (0.4 %) respectively. According to
trimester distribution, 53.8 % of the populations were
from third trimester. This was followed by women from
second trimester (26.9 %) and only 19.3 % from first
trimester.
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Complications observed
A total of 275 complications were observed which are
presented in Table 1.
The frequency distribution of the complications re-
vealed that 67 pregnant women (24.4 %) suffered from
various types of pain (back, abdominal, lower abdominal,
neck, pelvic pain), 40 (14.5 %) from nausea/vomiting, 20
(7.3 %) from acid reflux disease, 24 (8.7 %) from upper
respiratory tract infection, 14 (5.1 %) from per vaginal
bleeding and 19 (6.9 %) from urinary tract infection.
Of the total patients 75 (27.3 %) needed hospitalization.
Common reasons for hospitalization include abdominal
pain (n = 8), anemia (n = 1), diabetes mellitus (n = 1),
edema (n = 1) epilepsy (n = 1), fever/ headache (n = 6),
hyperemesis gravidarum (n = 5), hypothyroidism (n = 1),
loss of pregnancy (n = 9), lower abdominal pain (n = 3),
Table 1 Frequency distribution of complications
Complication 1st trimester (%) 2nd trimester (%) 3rd trimester (%) Total (%)
Alimentary tract and metabolism (n = 73) Acid reflux disease 2 (0.7 %) 8 (2.9 %) 10 (3.6 %) 20 (7.3 %)
Constipation 0 2 (0.7 %) 2 (0.7 %) 4 (1.5 %)
Diabetes mellitus 0 1 (0.4 %) 0 1 (0.4 %)
Diarrhoea 1 (0.4 %) 1 (0.4 %) 1 (0.4 %) 3 (1.1 %)
Hyperemesis gravidarum 5 (1.8 %) 0 0 5 (1.8 %)
Irritable bowel disease 0 0 1 (0.4 %) 1 (0.4 %)
Loss of appetite 0 2 (0.7 %) 0 2 (0.7 %)
Nausea/Vomiting 15 (5.5 %) 17 (6.2 %) 8 (2.9 %) 40 (14.5 %)
Blood and blood Anemia 1 (0.4 %) 0 0 1 (0.4 %)
Forming organs (n = 16) PV bleeding 5 (1.8 %) 0 9 (3.3 %) 14 (5.1 %)
Thrombocytopenia 0 0 1 (0.4 %) 1 (0.4 %)
Cardiovascular (n = 6) Pre-eclampsia 0 0 6 (2.2 %) 6 (2.2 %)
Dermatologicals (n = 7) Itching 0 2 (0.7 %) 5 (1.8 %) 7 (2.5 %)
Endocrinological (n = 6) Hypothyroidism 1 (0.4 %) 0 4 (1.5 %) 5 (1.8 %)
Pituitary adenoma 0 0 1 (0.4 %) 1 (0.4 %)
Genito-urinary (n = 20) PV discharge 0 0 8 (2.9 %) 8 (2.9 %)
Urinary tract infection 5 (1.8 %) 6 (2.2 %) 8 (2.9 %) 19 (6.9 %)
Anxiety 0 1 (0.4 %) 1 (0.4 %) 2 (0.7 %)
Depression 0 1 (0.4 %) 0 1 (0.4 %)
Nervous (n = 85) Epilepsy 1 (0.4 %) 0 1 (0.4 %) 2 (0.7 %)
Fever/Headache 2 (0.7 %) 2 (0.7 %) 6 (2.2 %) 10 (3.6 %)
Pain* 0 15 (5.5 %) 52 (18.9 %) 67 (24.4 %)
Psychosis 0 1 (0.4 %) 0 1 (0.4 %)
Tingling sensation 1 (0.4 %) 1 (0.4 %) 0 2 (0.7 %)
Asthma 0 2 (0.7 %) 1 (0.4 %) 3 (1.1 %)
Respiratory (n = 29) Pneumonia 0 0 1 (0.4 %) 1 (0.4 %)
Tuberculosis 1 (0.4 %) 0 0 1 (0.4 %)
Upper respiratory infections** 5 (1.8 %) 6 (2.2 %) 13 (4.7 %) 24 (8.7 %)
Sensory (n = 1) Dry eye 0 1 (0.4 %) 0 1 (0.4 %)
Edema 1 (0.4 %) 3 (1.1 %) 5 (1.8 %) 9 (3.3 %)
Loss of pregnancy 7 0 2 (0.7 %) 9 (3.3 %)
Various (n = 32) Oligohydramnios 0 0 1 (0.4 %) 1 (0.4 %)
Polyhydramnios 0 0 1 (0.4 %) 1 (0.4 %)
Weakness 0 2 (0.7 %) 0 2 (0.7 %)
Total 53 (19.3 %) 74 (26.9 %) 148 (53.8 %) 275 (100 %)
*total 67 pain complications seen were: abdominal pain (14), back pain (18), lower abdominal pain (30), neck pain (2), pelvic pain (3)
**upper respiratory tract infections consisted of cough cold and sore throat
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oligohydraminos (n = 1), pneumonia (n = 1), polyhydrami-
nos (n = 1), preeclampsia (n = 6), PV bleeding (n = 8), PV
discharge (n = 5), thrombocytopenia (n = 1), urinary tract
infections (n = 12) and upper respiratory tract infections
(n = 4) .
Association of complications with age of respondents
In 20–24 years age group, the patients were found to be
suffering mainly from pain (30, 46.2 %), nausea/vomiting
(17, 40.5 %), acid reflux disease (12, 60 %), urinary tract
infection (10, 52.6 %) and per vaginal bleeding (9,
64.3 %). In age group 25–29 years, major complications
were pain (19, 29.2 %), nausea/vomiting (14, 33.3 %),
and upper respiratory tract infection (11, 45.8 %). PV
bleeding, urinary tract infections, preeclampsia, loss of
pregnancy were seen in other age groups too. The com-
plications were not significantly associated with the age
of the patient (p 0.988) (Table 2).
Table 2 Association of complications with the age of the respondents
Complications Age of the respondents (in years) (n,%) Total p value
15–19 years 20–24 years 25–29 years 30–34 years 35–39 years 40–44 years
Acid reflux disease 1 (5) 12 (60) 5 (25) 2 (10) 0 0 20 (100) 0.988
Anemia 0 1 (100) 0 0 0 0 1 (100)
Anxiety 0 1 (50) 0 1 (50) 0 0 2 (100)
Asthma 0 2 (66.7) 1 (33.3) 0 0 0 3 (100)
Constipation 0 2 (50) 2 (50) 0 0 0 4 (100)
Depression 0 0 0 1 (100) 0 0 1 (100)
Diabetes mellitus 0 0 0 1 (100) 0 0 1 (100)
Diarrhea 0 0 2 (66.7) 1 (33.3) 0 0 3 (100)
Dry eye 0 1 (100) 0 0 0 0 1 (100)
Edema 0 5 (55.6) 2 (22.2) 1 (11.1) 1 (11.1) 0 9 (100)
Epilepsy 0 2 (100) 0 0 0 0 2 (100)
Fever/Headache 3 (30) 4 (40) 3 (30) 0 0 0 10 (100)
Hyperemesis gravidarum 0 2 (40) 3 (60) 0 0 0 5 (100)
Hypothyroidism 0 3 (60) 1 (20) 1 (20) 0 0 5 (100)
Irritable bowel disease 0 0 1 (100) 0 0 0 1 (100)
Itching 1 (14.3) 1 (14.3) 4 (57.1) 1 (14.3) 0 0 7 (100)
Loss of appetite 0 0 1 (50) 1 (50) 0 0 2 (100)
Loss of pregnancy 2 (22.2) 3 (33.3) 2 (22.2) 2 (22.2) 0 0 9 (100)
Nausea/Vomiting 9 (22.5) 16 (40) 14 (35) 1 (2.5) 0 0 40 (100)
Oligohydramnios 0 0 1 (100) 0 0 0 1 (100)
Pain 8 (11.9) 31 (46.3) 19 (28.4) 8 (11.9) 0 1 (1.5) 67 (100)
Pituitary adenoma 0 0 1 (100) 0 0 0 1 (100)
Pneumonia 0 0 1 (100) 0 0 0 1 (100)
Polyhrdramnios 0 0 1 (100) 0 0 0 1 (100)
Preeclampsia 1 (16.7) 2 (33.3) 2 (33.3) 1 (16.7) 0 0 6 (100)
Psychosis 1 (100) 0 0 0 0 0 1 (100)
PV bleeding 1 (7.1) 9 (64.3) 2 (14.3) 2 (14.3) 0 0 14 (100)
PV discharge 1 (12.5) 4 (50) 3 (37.5) 0 0 0 8 (100)
Thrombocytopenia 0 0 1 (100) 0 0 0 1 (100)
Tingling sensation 0 1 (50) 0 1 (50) 0 0 2 (100)
Total 34 (12.4) 121 (44) 90 (32.7) 27 (9.8) 2 (0.7) 1 (0.4) 275 (100)
Tuberculosis 0 0 1 (100) 0 0 0 1 (100)
Upper respiratory tract infection 5 (20.8) 7 (29.2) 11 (45.8) 1 (4.2) 0 0 24 (100)
Urinary tract infection 1 (5.3) 10 (52.6) 6 (31.6) 1 (5.3) 1 (5.3) 0 19 (100)
Weakness 0 2 (100) 0 0 0 0 2 (100)
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Association of complications with trimester of
respondents
Majority of the patients suffered from various complica-
tions in the third trimester. Besides pain, (52, 77.6 %),
upper respiratory tract infection (14, 58.3 %) and acid
reflux disease (10, 50 %) were the most frequently en-
countered complications in the third trimester. In the
second trimester acid reflux disease (8, 40 %), urinary
tract infections (6,31.6 %) and upper respiratory tract in-
fections (6, 25 %) were common. In the first trimester, the
pregnant patients suffered mainly from nausea/vomiting
(16, 38.1 %) and loss of pregnancy (7, 77.8 %). The compli-
cations were significantly associated with the trimester of
the pregnancy (p 0.000) (See Additional file 1).
Management of complications
Of the total 275 patients, 254 received a prescription for
iron, calcium and folic acid. Twenty two patients also
received prescriptions for tetanus toxoid injection and
34 received vitamins, nutritional supplements and other
alternative medicines. Eighty-six patients were not
prescribed with any medicines except multivitamins and
nutritional supplements.
For the management of pain hyoscine butylbromide
and diclofenac were most preferred. Likewise, paraceta-
mol and ibuprofen for fever and headache; ranitidine,
antacids and pantroprazole for acid reflux disorders; iron
for anemia; alprazolam in anxiety; salbutamol and ipra-
tropium bromide for asthma; bisacodyl and lactulose in
constipation; fluoxetine in depression; insulin for
diabetes mellitus; lamotrignine, carbamazepine, sodium
valporate, valporic acid for epilepsy; ondasetron, meto-
clopramide, domperidome, granisetron as antiemetics;
thyroxine for hypothyroidism; loratidine, levocetirizine,
cetirizine as antiallergics; tranaxemic acid for bleeding;
methyldopa, nifedipine, amlodipine, hydrochlorothiazide,
magnesium sulphate in pre-eclampsia; cefixime, nitrofur-
antoin, amoxicillin, ampicillin, ceftriaxone, gentamicin,
povidone iodine, metronidazole, piperacillin + tazobac-
tam combination, amoxicillin + potassium clavalunate
combination as anti-infectives; terbutaline, bromohexine,
guanefensin, oxymetazoline for cough and cold were the
commonly prescribed drugs for the management of
associated complications.
The common drugs that were prescribed in different
complications are presented in detail in Additional file 2.
Distribution of drugs
A total of 961 drugs (including nutritional supplements
and alternative medicines) have been prescribed to 275
patients. This consists of a minimum number zero (no
drug) to a maximum of 17 drugs in one patient present-
ing with eclampsia. The prescribed drugs when catego-
rized into generic class, a total of 93 different drugs have
been prescribed (excluding nutritional supplements and
alternative medicines). They were classified as per the
WHO ATC classification system and are presented in
Table 3.
Alimentary tract and metabolism drugs were the most
frequently prescribed drugs (36.3 %) which was followed
by drugs from blood and blood forming organs (26.6 %).
Anti-infectives for systemic use account for 14.8 % of
the total drugs prescribed which the third is highest in
the category.
Out of 961 drugs prescribed, iron, calcium and folic acid
given for routine supplementation account for 450 drugs
which is nearly 47 % of the total drugs prescribed. Besides
these, ranitidine is the most frequently prescribed drug
Table 3 Classification of drugs
ATC category 1st trimester (%) 2nd trimester (%) 3rd trimester (%) Total (%)
Alimentary tract and metabolism 44 (4.6 %) 94 (9.8 %) 211 (22 %) 349 (36.3 %)
Anti-infectives for systemic use 34 (3.5 %) 26 (2.7 %) 83 (8.6 %) 143 (14.9 %)
Antiparasitic products, insecticides and Repellants 1 (0.1 %) 0 1 (0.1 %) 2 (0.2 %)
Blood and blood forming organs 42 (4.4 %) 69 (4.4 %) 145 (15.1 %) 256 (26.7 %)
Cardiovascular system 0 0 19 (2 %) 19 (2 %)
Dermatologicals 0 3 (0.3 %) 3 (0.3 %) 6 (0.6 %)
Genitourinary system and sex hormones 13 (1.4 %) 2 (0.2 %) 7 (0.7 %) 22 (2.3 %)
Musculoskeletal system 1 (0.1 %) 2 (0.2 %) 9 (0.9 %) 12 (1,2 %)
Nervous system 13 (1.4 %) 11 1.1 %) 53 (5.5 %) 77 (8 %)
Respiratory system 6 (0.6 %) 14 (1.5 %) 16 (1.7 %) 36 (3.7 %)
Sensory organs 0 1 (0.1 %) 0 1 (0.1 %)
Systemic hormonal preparations exc.. Sex hormones and insulin 1 (0.1 %) 0 12 (1.2 %) 13 (1.4 %)
Various 5 (0.5 %) 4 (0.4 %) 16 (1.7 %) 25 (2.6 %)
Total 160 (16.6 %) 226 (23.5 %) 575 (59.8 %) 961 (100 %)
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accounting for 5.5 % of the total drugs prescribed. This is
then followed by hyoscine butylbromide (3.5 %), paraceta-
mol (3.5 %), ibuprofen + paracetamol combination (3.1 %),
ondansetron (2.9 %) and amoxicillin + potassium clavula-
nate combination (2.9 %).
The list of categorywise individual drugs have been
classified in Additional file 3.
Use of antimicrobials
A total of 18 different types of antimicrobial agents (ex-
cluding tetanus toxoid) have been used with a total
number counting to 123 which comprises of 12.8 % of
total drugs used. Majority of the antibiotics have been
used in severe hospitalized complications. The top four
antibiotics based on prescription frequency include
cefixime, amoxicillin, metronidazole and ceftriaxone.
Use of fixed dose combinations
Of the different fixed dose combinations, combination
of iron + folic acid is the maximum which accounts for a
total of 173 drugs out of 961. Except iron + folic acid a
total of 57 fixed dose combinations have been pre-
scribed. Of all these combinations ibuprofen + paraceta-
mol is maximum (30 out of 57).
Drug use per trimester
In an average 3.49 drugs have been used per patient.
Trimester wise drug use per patient is maximum in
the third trimester (3.88) followed by second (3.05)
and first (3.01).
Regarding the fact that both in patients and out-
patients cases have been considered in this study, it
would be necessary to see drug use per patient in these
two situations. The distribution of drugs and other par-
ameter differences between in patients and out patients
can be viewed from the Table 4. It is seen from the table
that the in-patients in an average receive 2.63 more
drugs than the outpatients.
Generic and brand prescribing
Of the total 275 prescriptions only 41 were prescribed
with generic drug names and the rest by brand names.
FDA pregnancy category and prescription of teratogenic
drugs
For the analysis of FDA pregnancy category of drugs and
identification of teratogenic drugs, we excluded the nutri-
tional supplements, vitamins and mineral supplements.
Out of 961 drugs, these included 479 drugs and the
analysis was done in remaining 482 drugs. The FDA preg-
nancy category of drugs has been presented in Fig. 1.
Majority of the medicines prescribed were from FDA
pregnancy category B (60.2 %) and C (23.4 %). 24 drugs
(4.9 %) prescribed from category D (n = 9) and X (n = 15)
were found to be teratogenic. Of the teratogenic drugs,
progesterone was most frequently prescribed (n = 9)
followed by misoprostol (n = 5), alprazolam (n = 2), povi-
done iodine (n = 2), carbamazepine (n = 1), human chori-
onic gonadotropin (n = 1), hydrochlorothiazine (n = 1),
hydroxyprogesterone (n = 1), phenobarbitone (n = 1) and
valporic acid (n = 1).
Dosage form of the drugs
Of the different dosage forms of drugs tablets were the
most frequently prescribed comprising of 61.4 % of the
total drugs prescribed. It was then followed by capsules,
injections and syrup which accounted for 21.8, 10.3 and
1.6 % of total prescribed drugs respectively. Remaining
were suspension, solution, drop, lotion, gel, ointment, in-
haler, granules and pressary. In the tablet dosage forms
calcium is the most prescribed one comprising of 33.6 %
Table 4 In patient and out patient differences
Parameter Out patient In-patient
Total population 200 (72.7 %) 75 (27.3 %)
Total number of drugs used 555 406













Mean duration of hospital stay Not applicable 4.65 days
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Fig. 1 FDA pregnancy categories of drugs
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of the total tablet dosage forms. Next to calcium are
ranitidine, folic acid, iron, paracetamol, cefixime and
ibuprofen + paracetamol combination each of which
constitute of 7.9, 7.1, 6, 5.5, 5.2 and 5 % of total tablet
dosage forms respectively. Others constitute the
remaining. In the capsules section, iron + folic acid com-
bination has the highest percentage of 82.3 % of all
capsule dosage form. This is followed by amoxicillin and
nifedipine in second and third places. The ascending
order of injection dosage form can be considered from
tetanus toxoid injection, ceftriaxone, hyoscine butylbro-
mide, metronidazole, dexamethasone, ondansetron and
ranitidine respectively each comprising of 22.2, 18.1,
11.1, 8, 7, 7 and 6 % of total drugs in injection form.
Discussion
As during other situations, pregnant women often suffer
from different types of complications. In this study we
found that nausea and vomiting was the most common
complication in the first and second trimester whereas
back pain and abdominal pain in the third trimester
which is most importantly associated with the physi-
ology of pregnancy. Cases of hospitalizations observed
were similar to a study which reports preterm labor,
genito urinary complications and preeclampsia as major
causes of hospitalizations [17]. Although the selection of
patients was not biased in terms of trimester majority of
the sampled women belonged to the third trimester.
This might need further clarification; however, it can
give us the idea that pregnant women frequently visited
the hospital during their late trimesters.
When we observed the management of complications we
found that 31.2 % of total prescriptions did not contain any
drugs besides multivitamins and nutritional supplements.
Hyoscine butylbromide, the most frequently prescribed
drug for abdominal pain is considered relatively safer in
pregnancy and normally not associated with adverse out-
comes in mother or neonates [18]. Even though rest and
manual therapy are suggested, acetaminophen and other
NSAIDS are reported as first line pain management drugs
during pregnancy [19, 20]. All antiemetics are considered
relatively safe during pregnancy and among them metoclo-
pramide and ondansetron are safer [4, 21, 22]. The use of
antibiotics was seen quite frequent for both prophylaxis
and treatment. Common antibiotics used here include
cefixime, nitrofuratoin, amoxicillin, ampicillin, ceftriax-
one, gentamycin. All these antibiotics are considered
relatively safe during pregnancy of which cephalospo-
rins and penicillins are considered safer. However, gen-
tamycin is associated with nephrotoxicity and might
need precaution before use [23].
Majority of the drugs prescribed in this study belonged
to FDA pregnancy category B and C and 3 different types
of drugs were from category X namely HCG, progesterone
and misoprostol. Misoprostol was basically used for in-
duction of abortion and in intra-uterine fetal death and
thus it’s use could be justified. A study [11] also shows
that majority of drugs taken by pregnant women were
from FDA pregnancy category C (28.8 %) and B (26.5 %)
and drugs from category D and X basically included pro-
gesterone and hormonal contraceptives respectively. Of
the FDA pregnancy category D drugs, antiepileptics have
been most frequently prescribed. Although being terato-
genic majority of antiepileptic drugs still lack much safer
alternative drugs [24]. Category B drugs are considered
relatively safe to use in pregnancy as animal studies have
failed to demonstrate any risk. However, category C drugs
should be used only when potential beneficial conditions
as these medicines have shown adverse effects on animal
studies. This shows that category C medications pre-
scribed here might need further assessment. However, lack
of ideally safe drugs and the need to treat the condition
outweigh the risks involved and a physician is compelled
to prescribe those drugs. With respect to prescription of
teratogenic drugs, the finding of this study was high as
compared to a study conducted in Pakistan which reports
2.3 % of the prescribed drugs as teratogenic [12].
In other complications the safest drugs possible have
been seen to be prescribed which reflect a positive as-
pect of prescribing. However, some anomalies were also
seen like use of amoxicillin in itching only, use of fixed
dose combinations when it might not be necessary and
use of drugs for which safer alternatives would be avail-
able. Safer alternatives could be chosen for alprazolam
in anxiety, hydrochlorothiazide in preeclampsia and
povidone iodine in respiratory tract infections.
In the drug utilization it is seen that average drug use
per patient is 3.49. As it is obvious that hospitalized
patients would receive higher number of drugs as com-
pared in outpatients, we attempted to calculate drugs
prescribed per patient among these two categories of pa-
tients. Our study showed that in an average 2.78 drugs
per prescription were prescribed to out-patients. A simi-
lar study [12] shows an average of 1.66 ± 0.14 drugs per
prescription among outpatients which is less as com-
pared to our study. Taking into consideration that ma-
jority of prescriptions contained iron, calcium and folic
acid, the number of drugs per patient is not a negative
reflection which means in general fewer drugs were pre-
scribed during pregnancy. This pattern is similar to
other studies conducted which show use of iron, calcium
and folic acid as the most frequently prescribed drugs dur-
ing pregnancy [5, 12, 13, 25, 26] . Besides these, drugs for
alimentary tract disorders, antiinfectives and nervous
system disorders have also been frequently prescribed. A
study [11] also shows analgesics (20 %), antibiotics
(12.6 %), gastrointestinal system drugs (12.1 %), gyenoco-
logic drugs (excluding antibiotics) (11.2 %) and central
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nervous system drugs (7.9 %) as the most frequently pre-
scribed drugs.
As much as 85 % of the prescriptions were prescribed
by brand names which shows that the practice of pre-
scribing drugs at OBG ward of study site is predomin-
antly brand name prescribing. Nearly 24 % of the drugs
were fixed dose combinations which is significantly less
as compared to previous studies where use of fixed dose
combination was higher (64.8 %) [5].
The occurrence of complications and the need for
drug use has always been a subject of interest when it is
related with pregnancy. Although the study site was a
single tertiary hospital, it is the major hospital of that re-
gion and the complications seen could be representative
of the nature of complications occurring in Western
Region of Nepal. Knowingly or unknowingly pregnant
women are taking drugs and physicians prescribing them
and in many instances when it goes wrong, the fetus is
the sufferer. Because pregnant patients might not know
about the safety profiles of the medicines prescribed to
them, it is the responsibility of the prescriber to pre-
scribe safe drugs during pregnancy. So, proper know-
ledge regarding medication use in pregnancy is highly
essential before any drug is prescribed.
Conclusion
A large number of complications during pregnancy were
observed. Besides pain and nausea/vomiting, acid reflux
disorders, upper respiratory tract infections, PV Bleeding,
urinary tract infections were frequently encountered. The
prescription of drugs to pregnant patients revealed the use
of drugs almost only when necessary and those considered
safe during pregnancy. However, few teratogenic drugs
(2.49 % of total drugs prescribed) were also found to be
prescribed which might need further assessments. More
than 90 % of the pregnant patients received nutritional
supplements of iron, calcium and folic acid.
Limitations of the study
The study was completed in only one centre and so this
data obtained from a tertiary care hospital cannot be
accounted as a representative data from several primary
and secondary care hospitals in Nepal. Also the study
only analysed the drugs prescribed but not the outcomes
of the therapy. So, the success of the therapy cannot be
measured from this study.
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